← All trials
NCT03809221
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2019
- Primary completion
- Sep 1, 2020
- Completion date
- Dec 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 1892
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Peking UniversityLead sponsor
- Peking UniversityCollaborator
- Peking UniversityReponsible party - principal investigator
- Zhengzhou UniversityCollaborator
- Hacettepe UniversityCollaborator
- Hebei UniversityCollaborator
- Sichuan UniversityCollaborator
- Henan Medical UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Peking UniversityOverall official - principal investigator
- Wenzhou Medical UniversityCollaborator
- Yinchuan Municipal Maternal and Child Health HospitalCollaborator
- Xinjiang Jiayin HospitalCollaborator
- Jiangxi Maternal and Child Health HospitalCollaborator
- Guangxi Maternal and Child Health HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.